Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Surgical Oncology
|
November 3, 2009
Gene expression profiling: decoding breast cancer
Femke de Snoo, Richard Bender, Annuska Glas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy
Bas Kreike, Hans Halfwerk, Petra Kristel, et al.
Breast Cancer Research and Treatment
|
March 23, 2016
Equivalence of MammaPrint array types in clinical trials and diagnostics
Inès Beumer, Anke Witteveen, Leonie Delahaye, et al.
Communications Biology
|
July 29, 2020
Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial
Laurent Jacob, Anke Witteveen, Inès Beumer, et al.
NPJ Breast Cancer
|
September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Denise M Wolf, Christina Yau, Ashish Sanil, et al.
The New England Journal of Medicine
|
December 20, 2002
A gene-expression signature as a predictor of survival in breast cancer
Marc J van de Vijver, Yudong D He, Laura J van't Veer, et al.
JCO Precision Oncology
|
June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Denise M Wolf, Christina Yau, Michael Campbell, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Surgical Oncology
|
November 3, 2009
Gene expression profiling: decoding breast cancer
Femke de Snoo, Richard Bender, Annuska Glas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy
Bas Kreike, Hans Halfwerk, Petra Kristel, et al.
Breast Cancer Research and Treatment
|
March 23, 2016
Equivalence of MammaPrint array types in clinical trials and diagnostics
Inès Beumer, Anke Witteveen, Leonie Delahaye, et al.
Communications Biology
|
July 29, 2020
Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial
Laurent Jacob, Anke Witteveen, Inès Beumer, et al.
NPJ Breast Cancer
|
September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Denise M Wolf, Christina Yau, Ashish Sanil, et al.
The New England Journal of Medicine
|
December 20, 2002
A gene-expression signature as a predictor of survival in breast cancer
Marc J van de Vijver, Yudong D He, Laura J van't Veer, et al.
JCO Precision Oncology
|
June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Denise M Wolf, Christina Yau, Michael Campbell, et al.
Page
of 1